Intradermal immunization improves protective efficacy of a novel TB vaccine candidate

Vaccine

Volumn 27, Issue 23, 2009, Pages 3063-3071

  Baldwin, Susan L ^a   Bertholet, Sylvie ^a   Kahn, Maria ^a   Zharkikh, Irina ^a   Ireton, Gregory C ^a   Vedvick, Thomas S ^a   Reed, Steven G ^a   Coler, Rhea N ^a  

^a INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

Author keywords

Mycobacterium tuberculosis; Subunit vaccine; TLR agonists

Indexed keywords

BACTERIAL PROTEIN; BCG VACCINE; GARDIQUIMOD; ID83 VACCINE; PROTEIN RV1813; PROTEIN RV2608; PROTEIN RV3620; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TUBERCULOSIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; FEMALE; HUMANS; IMMUNITY, CELLULAR; INJECTIONS, INTRADERMAL; INJECTIONS, SUBCUTANEOUS; MICE; MYCOBACTERIUM TUBERCULOSIS; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 9; TUBERCULOSIS VACCINES; TUBERCULOSIS, PULMONARY; VACCINES, SUBUNIT; VIRAL PROTEINS;

EID: 67349128324     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.03.018     Document Type: Article

References (44)

1. Dye C., Floyd F., and Uplekar M. Global tuberculosis control: surveillance, planning, financing: WHO report (2008), World Health Organization
2. Sander C., and McShane H. Translational mini-review series on vaccines: development and evaluation of improved vaccines against tuberculosis. Clinical and Experimental Immunology 147 March (3) (2007) 401-411
3. Dye C., Watt C.J., Bleed D.M., Hosseini S.M., and Raviglione M.C. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. Journal of the American Medical Association 293 June (22) (2005) 2767-2775
4. Andersen P., and Doherty T.M. The success and failure of BCG-implications for a novel tuberculosis vaccine. Nature Reviews 3 August (8) (2005) 656-662
5. Bertholet S., Ireton G.C., Kahn M., Guderian J., Mohamath R., Stride N., et al. Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis. The Journal of Immunology 181 11 (Dec) (2008) 7948-7957
6. Rook G.A., Hernandez-Pando R., Dheda K., and Teng Seah G. IL-4 in tuberculosis: implications for vaccine design. Trends in Immunology 25 September (9) (2004) 483-488
7. Seder R.A., Darrah P.A., and Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nature Reviews in Immunology 8 April (4) (2008) 247-258
8. Flynn J.L., Goldstein M.M., Triebold K.J., Koller B., and Bloom B.R. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proceedings of the National Academy of Sciences of the United States of America 89 December (24) (1992) 12013-12017
9. van Pinxteren L.A., Cassidy J.P., Smedegaard B.H., Agger E.M., and Andersen P. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. European Journal of Immunology 30 December (12) (2000) 3689-3698
10. Cooper A.M., Dalton D.K., Stewart T.A., Griffin J.P., Russell D.G., and Orme I.M. Disseminated tuberculosis in interferon gamma gene-disrupted mice. The Journal of Experimental Medicine 178 December (6) (1993) 2243-2247
11. Flynn J.L., Chan J., Triebold K.J., Dalton D.K., Stewart T.A., and Bloom B.R. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. The Journal of Experimental Medicine 178 December (6) (1993) 2249-2254
12. Russell D.G. Who puts the tubercle in tuberculosis?. Nature Reviews 5 January (1) (2007) 39-47
13. Bean A.G., Roach D.R., Briscoe H., France M.P., Korner H., Sedgwick J.D., et al. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. Journal of Immunology 162 March (6) (1999) 3504-3511
14. Flynn J.L., Goldstein M.M., Chan J., Triebold K.J., Pfeffer K., Lowenstein C.J., et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2 June (6) (1995) 561-572
15. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. The New England Journal of Medicine 345 October (15) (2001) 1098-1104
16. Pasare C., and Medzhitov R. Toll-like receptors: linking innate and adaptive immunity. Microbes and Infection/Institut Pasteur 6 December (15) (2004) 1382-1387
17. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., et al. A toll-like receptor recognizes bacterial DNA. Nature 408 December (6813) (2000) 740-745
18. Kaisho T., and Akira S. Toll-like receptors as adjuvant receptors. Biochimica et Biophysica Acta 1589 February (1) (2002) 1-13
19. Means T.K., Wang S., Lien E., Yoshimura A., Golenbock D.T., and Fenton M.J. Human toll-like receptors mediate cellular activation by Mycobacterium tuberculosis. Journal of Immunology 163 October (7) (1999) 3920-3927
20. Ferwerda G., Girardin S.E., Kullberg B.J., Le Bourhis L., de Jong D.J., Langenberg D.M., et al. NOD2 and toll-like receptors are nonredundant recognition systems of Mycobacterium tuberculosis. PLoS Pathogens 1 November (3) (2005) 279-285
21. Iwasaki A., and Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nature Immunology 5 October (10) (2004) 987-995
22. Sun J., Walsh M., Villarino A.V., Cervi L., Hunter C.A., Choi Y., et al. TLR ligands can activate dendritic cells to provide a MyD88-dependent negative signal for Th2 cell development. Journal of Immunology 174 January (2) (2005) 742-751
23. Napolitani G., Rinaldi A., Bertoni F., Sallusto F., and Lanzavecchia A. Selected toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nature Immunology 6 August (8) (2005) 769-776
24. Ghosh T.K., Mickelson D.J., Solberg J.C., Lipson K.E., Inglefield J.R., and Alkan S.S. TLR-TLR cross talk in human PBMC resulting in synergistic and antagonistic regulation of type-1 and 2 interferons, IL-12 and TNF-alpha. International Immunopharmacology 7 August (8) (2007) 1111-1121
25. Skeiky Y.A., Alderson M.R., Ovendale P.J., Guderian J.A., Brandt L., Dillon D.C., et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. Journal of Immunology 172 June (12) (2004) 7618-7628
26. Wang B., Henao-Tamayo M., Harton M., Ordway-Rodrigues D., Shanley C., Basaraba R.J., et al. A toll-like receptor-2 directed fusion protein vaccine against tuberculosis. Clinical and Vaccine Immunology 14(July) (2007) 902-906
27. Zaks K., Jordan M., Guth A., Sellins K., Kedl R., Izzo A., et al. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. Journal of Immunology 176 June (12) (2006) 7335-7345
28. Baldwin S.L., D'Souza C., Roberts A.D., Kelly B.P., Frank A.A., Lui M.A., et al. Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis. Infection and Immunity 66 June (6) (1998) 2951-2959
29. Mosmann T.R., and Coffman R.L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annual Review of Immunology 7 (1989) 145-173
30. Teloni R., von Hunolstein C., Mariotti S., Donati S., Orefici G., and Nisini R. Antibody classes & subclasses induced by mucosal immunization of mice with Streptococcus pyogenes M6 protein & oligodeoxynucleotides containing CpG motifs. The Indian Journal of Medical Research 119 May (Suppl.) (2004) 126-130
31. Fransen F., Boog C.J., van Putten J.P., and van der Ley P. Agonists of toll-like receptors 3 4, 7, and 9 are candidates for use as adjuvants in an outer membrane vaccine against Neisseria meningitidis serogroup B. Infection and Immunity 75 December (12) (2007) 5939-5946
32. Diebold S.S., Kaisho T., Hemmi H., Akira S., and Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303 March (5663) (2004) 1529-1531 (New York, NY)
33. Edwards A.D., Diebold S.S., Slack E.M., Tomizawa H., Hemmi H., Kaisho T., et al. Toll-like receptor expression in murine DC subsets: lack of TLR7 expression by CD8 alpha+ DC correlates with unresponsiveness to imidazoquinolines. European Journal of Immunology 33 April (4) (2003) 827-833
34. Ito T., Amakawa R., Kaisho T., Hemmi H., Tajima K., Uehira K., et al. Interferon-alpha and interleukin-12 are induced differentially by toll-like receptor 7 ligands in human blood dendritic cell subsets. The Journal of Experimental Medicine 195 June (11) (2002) 1507-1512
35. Burns Jr. R.P., Ferbel B., Tomai M., Miller R., and Gaspari A.A. The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells. Clinical Immunology 94 January (1) (2000) 13s-23s (Orlando, Fla)
36. Suzuki H., Wang B., Shivji G.M., Toto P., Amerio P., Tomai M.A., et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. The Journal of Investigative Dermatology 114 January (1) (2000) 135-141
37. Debenedictis C., Joubeh S., Zhang G., Barria M., and Ghohestani R.F. Immune functions of the skin. Clinics in Dermatology 19 September-October (5) (2001) 573-585
38. Valladeau J., and Saeland S. Cutaneous dendritic cells. Seminars in Immunology 17 August (4) (2005) 273-283
39. Griffiths C.E., Dearman R.J., Cumberbatch M., and Kimber I. Cytokines and Langerhans cell mobilisation in mouse and man. Cytokine 32 October (2) (2005) 67-70
40. Stahl J., Niedorf F., and Kietzmann M. Characterisation of epidermal lipid composition and skin morphology of animal skin ex vivo. European Journal of Pharmaceutics and Biopharmaceutics (2008) 10.1016/j.ejpb.2008.09.013
41. Lee Y., and Hwang K. Skin thickness of Korean adults. Surgical and Radiologic Anatomy 24 August-September (3-4) (2002) 183-189
42. Zhang W.W., and Matlashewski G. Immunization with a toll-like receptor 7 and/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB/c mice. Infection and Immunity 76 August (8) (2008) 3777-3783
43. Turner O.C., Basaraba R.J., and Orme I.M. Immunopathogenesis of pulmonary granulomas in the guinea pig after infection with Mycobacterium tuberculosis. Infection and Immunity 71 February (2) (2003) 864-871
44. Darrah P.A., Patel D.T., De Luca P.M., Lindsay R.W., Davey D.F., Flynn B.J., et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nature Medicine 13 July (7) (2007) 843-850